It then appeared a high level of Zeb1 might be necessary to maintain CD44 through a miR-200-independent pathway, or CD44 expression is reduced in cancer cells via a dominant Zeb1-independent mechanism (see below). The gene discussed is ZEB1; the disease is cancer.